Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -0.02% | 177.14 | 0.7% | $1156.72m | |
| LLY | Eli Lilly & Co. | -0.67% | 369.47 | 1.1% | $1061.48m | |
| MRK | Merck & Co., Inc. | 0.35% | 110.48 | 0.7% | $1006.19m | |
| PFE | Pfizer Inc. | 2.52% | 51.51 | 0.9% | $959.31m | |
| ABBV | AbbVie, Inc. | 0.13% | 165.61 | 1.9% | $896.70m | |
| BMY | Bristol-Myers Squibb Co. | -0.35% | 79.65 | 1.1% | $739.40m | |
| AZN | AstraZeneca Plc | 0.81% | 69.41 | 1.0% | $357.25m | |
| HZNP | Horizon Therapeutics Plc | 1.65% | 97.89 | 5.4% | $291.17m | |
| GSK | GSK Plc | -0.17% | 36.82 | 0.3% | $250.64m | |
| IDXX | IDEXX Laboratories, Inc. | 1.78% | 427.60 | 3.9% | $194.80m | |
| NVS | Novartis AG | -0.35% | 91.41 | 0.2% | $187.82m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 2.76% | 237.70 | 8.0% | $172.78m | |
| CTLT | Catalent, Inc. | -3.98% | 45.34 | 1.9% | $163.63m | |
| NVO | Novo Nordisk A/S | 1.63% | 127.28 | 0.1% | $154.53m | |
| SNY | Sanofi | -1.73% | 47.11 | 0.2% | $135.70m |
Company Profile
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.